Patents Assigned to Gloriana Therapeutics, sarl
  • Mammalian Cell Culture-Produced Neublastin Antibodies
    Publication number: 20220048984
    Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 17, 2022
    Applicant: GLORIANA THERAPEUTICS SARL
    Inventors: Alan Gilbert, Kyle Mcelearney, Terrance Michael Dobrowsky, Rashmi Riohit Kshirsagar
  • Cell lines and their use in encapsulated cell biodelivery
    Patent number: 10888526
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 12, 2021
    Assignee: GLORIANA THERAPEUTICS SARL
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Anti-neublastin antibodies and uses thereof
    Patent number: 10047150
    Abstract: Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: August 14, 2018
    Assignee: GLORIANA THERAPEUTICS SARL
    Inventors: Anthony Rossomando, Ping Jin
  • Cell lines and their use in encapsulated cell biodelivery
    Patent number: 9884023
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: February 6, 2018
    Assignee: Gloriana Therapeutics sarl
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Implantable Cell Device with Supportive and Radial Diffusive Scaffolding
    Publication number: 20170232186
    Abstract: The invention features an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.
    Type: Application
    Filed: April 30, 2017
    Publication date: August 17, 2017
    Applicant: Gloriana Therapeutics sarl
    Inventors: Lars Ulrik Wahlberg, Jens Tornøe
  • Implantable cell device with supportive and radial diffusive scaffolding
    Patent number: 9669154
    Abstract: The invention features an implantable cell device. The device includes a membrane defining and enclosing a chamber; a distance body, within the chamber, for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold, within the chamber, for increasing the cell support surface area per unit volume of the chamber for distributing cells.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: June 6, 2017
    Assignee: Gloriana Therapeutics, sarl
    Inventors: Lars Ulrik Wahlberg, Jens Tornøe